Following the European artificial intelligence act, EMA and HMA have proposed a workplan from 2024 to 2028 to balance the risk-benefits of AI in drug development. The workplan addresses 4 critical AI dimensions: policies, tools, training and experiments. As part of pharmaceutical data intelligence, AI is rapidly and profoundly moving into each field of medicines discovery and development.
Artificial intelligence workplan to guide use of AI in medicines regulation
Published on December 19, 2023
Other news
